Provided by Tiger Trade Technology Pte. Ltd.

Ultragenyx Pharmaceutical

14.30
-0.1000-0.69%
Post-market: 14.350.0500+0.35%19:07 EDT
Volume:3.25M
Turnover:46.57M
Market Cap:1.41B
PE:-2.45
High:14.70
Open:14.43
Low:14.13
Close:14.40
52wk High:39.89
52wk Low:13.81
Shares:98.32M
Float Shares:80.72M
Volume Ratio:0.31
T/O Rate:4.03%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-5.8279
EPS(LYR):-5.8316
ROE:-608.47%
ROA:-24.22%
PB:-4.83
PE(LYR):-2.45

Loading ...

Analysts Offer Insights on Healthcare Companies: Merck & Company (MRK), Intellia Therapeutics (NTLA) and Ultragenyx Pharmaceutical (RARE)

TIPRANKS
·
Sep 08

Ultragenyx price target lowered to $32 from $43 at Barclays

TIPRANKS
·
Sep 04

Sector Update: Healthcare Stocks Higher Thursday Afternoon

MT Newswires Live
·
Sep 04

Nvidia, Tesla, Robinhood, Snowflake, Ultragenyx, Ciena, and More Stocks That Explain Today's Market

Dow Jones
·
Sep 04

Ultragenyx downgraded to Equal Weight from Overweight at Morgan Stanley

TIPRANKS
·
Sep 04

Ultragenyx falls -44.0%

TIPRANKS
·
Sep 04

Ultragenyx Pharmaceutical Down over 45%, on Pace for Record Low Close and Record Percent Decrease

Dow Jones
·
Sep 03

Ultragenyx Hits Record Low After Rare Disease Drug Trial Failure

Reuters
·
Sep 03

Why Is Ultragenyx Pharmaceutical Stock (RARE) Down Today?

TIPRANKS
·
Sep 03

U.S. Stocks on the MOVE-Gold Miners, Polestar Automotive, Nvidia

Reuters
·
Sep 03

Ultragenyx price target lowered to $28 from $77 at Jefferies

TIPRANKS
·
Sep 03

Wedbush Keeps Their Hold Rating on Ultragenyx Pharmaceutical (RARE)

TIPRANKS
·
Sep 03

Ultragenyx price target lowered to $33 from $103 at Cantor Fitzgerald

TIPRANKS
·
Sep 03

Analysts Offer Insights on Healthcare Companies: Ultragenyx Pharmaceutical (RARE) and Lifecore Biomedical (LFCR)

TIPRANKS
·
Sep 03

Ultragenyx Stock Sinks 47% on Drug Trial Failure. Why Wall Street Isn't Giving up Yet.

Dow Jones
·
Sep 03

U.S. Stocks on the MOVE-Snowflake, Ultragenyx Pharmaceutical, Broadcom

Reuters
·
Sep 03

Top Premarket Decliners

MT Newswires Live
·
Sep 03

Wedbush Adjusts Price Target on Ultragenyx Pharmaceutical to $23 From $30, Maintains Neutral Rating

MT Newswires Live
·
Sep 03

Canaccord Genuity Sticks to Its Buy Rating for Ultragenyx Pharmaceutical (RARE)

TIPRANKS
·
Sep 03

Ultragenyx price target lowered to $37 from $83 at Canaccord

TIPRANKS
·
Sep 03